tiprankstipranks
Psychemedics Corp. (PMD)
NASDAQ:PMD
US Market

Psychemedics (PMD) Stock Price & Analysis

107 Followers

PMD Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$2.06 - $5.97
Previous Close$2.96
Volume24.04K
Average Volume (3M)13.61K
Market Cap
$16.94M
Enterprise Value$18.21M
Total Cash (Recent Filing)$1.37M
Total Debt (Recent Filing)$2.64M
Price to Earnings (P/E)-4.4
Beta0.04
May 07, 2024
EPS EstimateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding5,801,761
10 Day Avg. Volume16,343
30 Day Avg. Volume13,607
Standard Deviation0.12
R-Squared0.08
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)2.28
Price to Sales (P/S)0.68
Price to Cash Flow (P/CF)-3.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.80
Enterprise Value/Gross Profit1.96
Enterprise Value/Ebitda-5.59
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

25.34%9.16%13.22%52.28%
25.34% Insiders
13.22% Other Institutional Investors
52.28% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks

PMD FAQ

What was Psychemedics Corp.’s price range in the past 12 months?
Psychemedics Corp. lowest stock price was $2.06 and its highest was $5.96 in the past 12 months.
    What is Psychemedics Corp.’s market cap?
    Currently, no data Available
    When is Psychemedics Corp.’s upcoming earnings report date?
    Psychemedics Corp.’s upcoming earnings report date is May 07, 2024 which is in 40 days.
      How were Psychemedics Corp.’s earnings last quarter?
      Currently, no data Available
      Is Psychemedics Corp. overvalued?
      According to Wall Street analysts Psychemedics Corp.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Psychemedics Corp. pay dividends?
        Psychemedics Corp. pays a Thriceyearly dividend of $0.07 which represents an annual dividend yield of 9.59%. See more information on Psychemedics Corp. dividends here
          What is Psychemedics Corp.’s EPS estimate?
          Psychemedics Corp.’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Psychemedics Corp. have?
          Psychemedics Corp. has 5,801,761 shares outstanding.
            What happened to Psychemedics Corp.’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Psychemedics Corp.?
            Currently, no hedge funds are holding shares in PMD
            ---

            Psychemedics Stock Smart Score

            N/A
            Not Ranked
            1
            2
            3
            4
            5
            6
            7
            8
            9
            10

            Technicals

            SMA
            Negative
            20 days / 200 days
            Momentum
            -48.53%
            12-Months-Change

            Fundamentals

            Return on Equity
            -40.70%
            Trailing 12-Months
            Asset Growth
            -31.13%
            Trailing 12-Months

            Company Description

            Psychemedics Corp.

            Psychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. It specializes in a five panel drug testing process for cocaine, opioids, Phenyclidine, amphetamines, and marijuana. It offers workplace, school, and personal drug testing services. The company was founded by Werner Baumgartner and Annette Baumgartner on September 24, 1986 and is headquartered in Acton, MA.
            ---
            Similar Stocks
            Company
            Price & Change
            Follow
            Alcon
            Charles River Labs
            QuidelOrtho
            Illumina
            Popular Stocks
            ---
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis